Nondopamine antipsychotic shows clinical signal in Parkinson’s disease psychosis
Pediatric News ,
SEP-363856, an investigational nondopamine antipsychotic that’s been the focus of a trial in schizophrenia, has shown signals…
SEP-363856, an investigational nondopamine antipsychotic that’s been the focus of a trial in schizophrenia, has shown signals…
SEP-363856, an investigational nondopamine antipsychotic that's been the focus of a trial in schizophrenia, has shown signals…
Acadia (ACAD) dodged the worst of the undertow that has swamped so many speculative biotechs in recent months.
Summary Lead product sales are ramping up for NUPLAZID, indicated for Parkinson's delusions and hallucination.
. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin.